Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.
CEO to address investor audiences at two New York events in mid-October
Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City, followed by a presentation at the ThinkEquity Conference on October 15, 2026, also in New York City. Both appearances target biotechnology investors evaluating the company's pipeline.
Nu-3 preclinical data to be presented at IDWeek in Washington
On October 22, 2026, Cooper will present a poster covering preclinical data on Nu-3 at IDWeek in Washington, D.C., an infectious disease-focused conference. The presentation gives the company direct access to clinicians and researchers tracking antibiotic-resistant pathogens.
Bisphosphocin class targets drug-resistant bacterial strains including MRSA and VRE
Lakewood-Amedex is developing its proprietary Bisphosphocin class of fast-acting, broad-spectrum antimicrobials aimed at infectious diseases caused by antibiotic-resistant strains such as MRSA and VRE. The three-conference circuit is intended to expand visibility for the company's development programs among both capital markets and the infectious disease research community.